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This paper demonstrates that the introduction of large-core needle biopsy (LCNB) replacing needle-localised breast biopsy (NLBB)
for nonpalpable (screen-detected) breast lesions could result in substantial cost savings at the expense of a possible slight increase in
breast cancer mortality. The cost-effectiveness of LCNB and NLBB was estimated using a microsimulation model. The sensitivity of
LCNB (0.97) and resource use and costs of LCNB and NLBB were derived from a multicentre consecutive cohort study among 973
women who consented in getting LCNB and NLBB, if LCNB was negative. Sensitivity analyses were performed. Replacing NLBB with
LCNB would result in approximately six more breast cancer deaths per year (in a target population of 2.1million women), or in 1000
extra life-years lost from breast cancer (effect over 100 years). The total costs of management of breast cancer (3% discounted) are
estimated at d4676 million with NLBB; introducing LCNB would save d13 million. The incremental cost-effectiveness ratio of
continued NLBB vs LCNB would be d12482 per additional life-year gained (3% discounted); incremental costs range from d-21687
(low threshold for breast biopsy) to d74378 (high sensitivity of LCNB).
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In Western societies, breast cancer is the most common
malignancy in women. This disease and the ensuing mortality
are considered the major public health problems. Mass screening
for breast cancer is deemed effective in reducing breast cancer
mortality. Studies have shown that early detection of breast cancer
may reduce breast cancer mortality (Nystrom et al, 2002; Otto et al,
2003). As a result of screening, nonpalpable small breast lesions
are increasingly detected.
Open-breast biopsy has long been considered the gold standard
to determine malignancy in palpable and nonpalpable lesions.
Despite excellent test characteristics (Verkooijen et al, 2000),
open-breast biopsy has disadvantages. The surgical procedure may
cause anxiety, morbidity or even mortality, and may leave women
with a permanent deformation and scar of the breast. Women may
need to be hospitalised and high-cost surgical and anaesthetic
resources are used. In search of clinically equivalent less invasive
diagnostic alternatives, stereotactic large-core needle biopsy
(LCNB) has been introduced, particularly for nonpalpable lesions
(Gisvold et al, 1994; Britton et al, 1997; Pijnappel et al, 1997;
Jackman et al, 1999).
A decision analytic approach based on data obtained from
literature suggested that core biopsy and open-breast biopsy may
be clinically equivalent, core biopsy being less costly than open-
breast biopsy (Hrung et al, 1999). Prior to our study, actual direct
empirical comparison of the diagnostic procedures had not been
performed. In a multicentre clinical study, both techniques were
compared (Verkooijen, 2000). Using a validated microsimulation
model, we set out to assess the effect of stereotactic LCNB
replacing conventional needle-localised breast biopsy (NLBB) as
diagnostic procedure in women with nonpalpable screen-detected
breast lesions in terms of breast cancer mortality, life-years and
cost-effectiveness.
MATERIALS AND METHODS
Clinical study – the COBRA study
The test characteristics of stereotactic LCNB (14-gauge) were
obtained from a prospective multicentre consecutive cohort study
(the COBRA study) (Verkooijen, 2002). This study was performed
between April 1997 and February 2000 to assess the diagnostic
accuracy of LCNB, as compared to NLBB in women with
nonpalpable breast lesions. After having given informed consent
to participate in the study, the women underwent core biopsy first.
Biopsies were done by specially trained radiologists; at least five
biopsy specimens were obtained from each lesion. After the core
biopsy, all women underwent open-breast biopsy as well (gold
standard); they underwent therapeutic surgery when the LCNB
yielded breast cancer or NLBB in cases of LCNB without
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lmalignancy. In total, 973 consecutive women (1029 lesions) were
enrolled. In 813 women (858 lesions), the LCNB procedure could
be completed successfully. Three possible outcomes of LCNB were
distinguished: (1) malignancy; (2) benign lesion; (3) inconclusive
result (normal tissue, high-risk lesion). In the case of an
inconclusive result, additional NLBB has been recommended
(Verkooijen, 2002). In our study, the sensitivity of LCNB was
calculated including this second-step diagnostic procedure for
inconclusive results.
Structure of the microsimulation model
To study the impact of LCNB and NLBB on health effects and
costs, we used the simulation model MISCAN (van Oortmarssen
et al, 1990; Boer et al, 1995; de Koning et al, 1995). The micro-
simulation screening analysis program was originally designed to
evaluate the introduction of mass screening for breast cancer and
to support related decision-making (de Koning et al, 1991; van den
Akker-van Marle et al, 1997; Boer et al, 1998). The model is
described in more detail in Appendix A. In summary, the core of
the model consists of ‘simulated life histories’ including the natural
history of breast cancer. The natural history is modelled as the
onset of breast cancer, the transition through four possible
preclinical invasive stages with increasing tumour diameters
(T1a, T1b, T1c and T2þ) and the transition from one of
the preclinical stages into a clinically diagnosed stage (DCIS,
T1a, T1b, T1c or T2þ) until the women die from breast cancer
or from other causes. Breast cancer screening is introduced as
an intervention in the natural history, possibly resulting in the
detection of breast cancer in earlier (preclinical, presymptomatic)
stages.
The output of the model yields a number of estimates of the
effect of screening and subsequent outcome. The numbers of
women invited and screened are assessed, as well as the resulting
number of true-positive and false-positive test results, and the
number of cancers diagnosed outside the screening programme.
The output also includes the numbers of diagnostic procedures for
breast tumours detected by screening and for breast cancers
detected outside the context of the breast cancer-screening
programme, and the number of breast cancer therapies. Moreover,
the model calculates the number of breast cancer deaths and life-
years lost due to cancer.
Cost-effectiveness was calculated by adding a profile of costs
over time to each disease state.
Model assumptions
Screening programme In the model, we assumed a breast cancer-
screening programme lasting 27 years. This programme implies
biennial screening mammography for women aged 50–75 years, in
accordance with the current screening policy in the Netherlands
(current target population: 2.1 million women). Health effects were
considered for the remaining life expectancy of the cohort
simulated (maximum age 100 years).
Diagnostic scenarios We simulated three scenarios: (A) the
situation without mass screening; (B) mass screening with NLBB
as diagnostic work-up for palpable and nonpalpable breast lesions;
and (C) mass screening with LCNB replacing NLBB as diagnostic
work-up for nonpalpable lesions, followed by NLBB if the core
biopsy indicates normal breast tissue or a high-risk lesion
(Verkooijen, 2000). We used the data from our empirical study
to quantify the relevant stages in the diagnostic scenarios. Figure 1
shows the diagnostic strategies (B) and (C) for nonpalpable screen-
detected breast lesions. In scenario (B), after a positive screen
examination, women with nonpalpable lesions will be scheduled
for NLBB, unless diagnostic mammography or fine needle
aspiration (FNA) cytology indicate no malignancy (‘not suspect’).
Preoperative FNA cytology precedes about one-third of NLBB
procedures in nonpalpable breast lesions. In scenario (C), women
with a positive screen examination are scheduled for LCNB, unless
diagnostic mammography indicates the absence of malignancy
(‘not suspect’). Preceding LCNB, no FNA cytology is assumed.
Women in scenario (C) will undergo NLBB if LCNB is contra-
indicated, if LCNB is cancelled (for reasons including too small
breasts for adequate compression, negative stroke margins,
patients not enduring prone position or lesions being localised
too close to the chest wall), if the tissue samples obtained by LCNB
are nonrepresentative, or if tissue samples indicate normal breast
tissue or a ‘high-risk’ lesion. Among the contraindications for
LCNB are coagulopathy, anticoagulant use and the inability to
maintain prone position for 1h. If invasive cancer or DCIS is
diagnosed, women undergo definite treatment, that is, breast-
conserving therapy or mastectomy, or surgical excision, respec-
tively. Women with benign lesions are offered follow-up mammo-
graphy. Women with screen-detected breast lesions that are
palpable and women with breast lesions detected outside the
screening programme are considered to undergo open-breast
biopsy (not shown in Figure 1).
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Figure 1 Diagnostic procedures for nonpalpable breast lesions detected
at screening (model input). Needle-localised breast biopsy (scenario (B))
and LCNB (scenario (C)), FNA¼fine needle aspiration (cytology), malign:
invasive breast carcinoma or ductal carcinoma in situ, nonconclusive: normal
tissue or high-risk lesion.
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lTest characteristics NLBB was considered to be the gold standard
diagnostic procedure with 100% sensitivity. The test characteristics
of LCNB were obtained from the COBRA study.
Costs
Diagnostic phase The costs of the diagnostic phase were
calculated as the resource use in the diagnostic stage multiplied
with cost-per-unit estimates. The relevant resource items were
LCNB, NLBB, histopathological examination, hospitalisation, day
care, general practitioner (GP), diagnostic mammography, other
diagnostic procedures (e.g. ultrasound and MR imaging), FNA and
outpatient visit. The actual economic costs per unit of LCNB,
NLBB and histopathological examination were obtained from five
participating Dutch hospitals. Due to practice variation, the costs
of hospitalisation for diagnostic excision biopsy were averaged for
treatment setting (day care for about half of the biopsies, and
hospitalisation for the other half with a mean hospital stay of 3
days) (Buijs-van der Woude et al, 2001). The costs per unit of
resource use were calculated as actual economic costs, that is,
including medical staff, other personnel, disposables, fixed
equipment and a mark-up for fixed costs and overheads (Finkler,
1982). The costs of GP care and outpatient visits were based on
Dutch reference guidelines (Oostenbrink et al, 2000).
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lTreatment phase The costs of breast cancer treatment were
obtained from previous studies (de Koning et al, 1991).
Reimbursement fees were used to estimate the costs of primary
and adjuvant therapies. The costs of palliative care were obtained
from studying the records of patients with breast cancer
metastases.
Costs were originally calculated in Dutch currency and
converted into UKd using the 2002 purchasing-power parity
(PPP: DFL 1.00¼UKd0.312). To take account of time preference,
the costs estimates over time were adjusted with 3% (baseline)
and 5% (sensitivity analysis) annual discount rate. To compute
the cost-effectiveness, equal discount rates were applied to the
effects as well (Lipscomb et al, 1996). Costs and references
are summarised in Table 1.
Sensitivity analysis
Sensitivity analysis was performed to quantify the impact of
variations in essential model parameters and assumptions on cost-
effectiveness (Table 1).
First, the sensitivity of LCNB for DCIS and invasive breast
lesions was varied using the limits of the 95% confidence intervals.
Second, the costs of LCNB were varied: the low and high LCNB
costs correspond to the case where LCNB is employed highly
concentrated in 10 of all Dutch hospitals or decentralised (in all
114 Dutch hospitals), respectively (Buijs-van der Woude et al,
2001).
Third, the costs in the NLBB scenario were varied, assuming that
all NLBBs were done in day care, taking into account that there will
Table 1 Model parameters and range of sensitivity analyses
Parameter Base case Sensitivity analyses Reference or source
Test performance
Sensitivity of NLBB 1.00 Assumed
Sensitivity of LCNB
a 0.97 0.96/0.99
b COBRA study
Probability of nonmalignant diagnosis of a nonpalpable lesion after
Diagnostic mammography/further assessment 0.30 0.15/0.00 Dutch BCSP
Cytology (FNA) 0.25 Dutch BCSP
NLBB 0.38 Dutch BCSP
LCNB 0.50 (Verkooijen, 2000)
Preoperative FNA for nonpalpable lesions (scenario (B)) 0.29 (Pijnappel et al, 2001)
Contraindication for LCNB (scenario (C)) 0.15 COBRA study
Unsuccessful LCNB (cancelled or nonrepresentative material) (scenario (C)) 0.08 COBRA study
Proportion of nonpalpable suspicious breast lesions at screening by mammography 760%
c 775%
d Assumed/(BreastScreen Victoria, 2000)
Costs
Diagnostic stage
General practitioner d12 (Oostenbrink et al, 2000)
Diagnostic mammogram d56 (de Koning et al, 1991)
MR imaging d264 (de Koning et al, 1991)
Ultrasound (additional costs only) d9 (de Koning et al, 1991)
FNA d54 (de Koning et al, 1991)
Outpatient visit d30 (Oostenbrink et al, 2000)
LCNB d343 d189–611 (Buijs-van der Woude et al, 2001)
NLBB d374 (Buijs-van der Woude et al, 2001)
Admission or hospitalisation d267
e (Buijs-van der Woude et al, 2001)
Wire localisation d90 (Buijs-van der Woude et al, 2001)
Histopathological examination
LCNB d61 (Buijs-van der Woude et al, 2001)
NLBB d120 (Buijs-van der Woude et al, 2001)
Follow-up in disease-free stage (per year)
First disease-free year d125 (de Koning et al, 1991)
Every following year d88 (de Koning et al, 1991)
Primary therapy
BCT, without booster (invasive tumours) d4046 (de Koning et al, 1991)
BCT, internal booster (invasive tumours) d5558 (de Koning et al, 1991)
BCT, external booster (invasive tumours) d4774 (de Koning et al, 1991)
Mastectomy followed by radiotherapy (invasive tumours) d3638 (de Koning et al, 1991)
Mastectomy without radiotherapy (invasive tumours) d2091 (de Koning et al, 1991)
Excision followed by radiotherapy (DCIS) d2563 (de Koning et al, 1991)
Excision without radiotherapy (DCIS) d310 (de Koning et al, 1991)
Amputation (DCIS) d1749 (de Koning et al, 1991)
Adjuvant therapy
Chemotherapy d1020 (de Koning et al, 1991)
Hormonal therapy d561 (de Koning et al, 1991)
Palliative treatment
M0 (no metastasis) d12158 (de Koning et al, 1991)
M1 (metastatic disease) d12158 (de Koning et al, 1991)
BCSP¼breast cancer-screening programme; BCT¼breast-conserving therapy.
aLCNB, including additional open-breast biopsy in the case of normal tissue or high-risk lesion.
bLower and upper limit of the 95% confidence interval of the sensitivity. The sensitivity of LCNB for DCIS is 0.94 (95% CI 0.90–0.97), for invasive carcinoma 0.99 (0.99–1.00).
cTumour stages DCIS, T1a and T1b are considered to involve nonpalpable breast tumours.
dNonpalpable and palpable breast tumours are distributed over all tumour stages: as
the size of the tumours increased, a smaller proportion was nonpalpable(2000).
eThe mean cost of hospitalisation for all NLBBs; half of such biopsies were performed in day care;
in the other half of cases, hospitalisation was necessary (the mean hospital stay for all open breast biopsies was 3 days) (Buijs-van der Woude et al, 2001).
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admission: d137).
Fourth, we simulated LCNB scenarios where 100 or 85% of
referred women, respectively, would have further histopathologic
assessment after clinical mammography and physical examination.
Finally, we varied the distribution of nonpalpable lesions at
screening. In the basic model, all DCIS and lesions o1cm in
diameter (i.e. T1a and T1b) were considered nonpalpable, whereas
T1c and T2þ lesions were regarded palpable. As a high estimate,
we considered 75% of all lesions to be nonpalpable, with the
proportion of nonpalpable tumours gradually decreasing with
tumour size (BreastScreen Victoria, 2000).
RESULTS
Sensitivity of LCNB
Of the nonpalpable breast lesions, 58% (494 of 858) were malignant
according to the gold standard: 20% (172 of 858) involved ductal
carcinoma in situ (DCIS) and 38% (322 of 858) invasive carcinoma.
With the LCNB procedure, 481 of 494 malignancies were detected:
malignancy being the initial diagnosis at core biopsy (470 cases) or
the diagnosis at surgery following a nonconclusive diagnosis
(normal tissue or ‘high-risk’ lesion) at core biopsy (11 cases).
Thus, the overall sensitivity of the LCNB procedure was 0.97 (95%
CI: 0.96–0.99). The sensitivity for DCIS was 0.94 (161 of 172) (95%
CI: 0.90–0.97) and for invasive breast cancer 0.99 (320 of 322)
(95% CI: 0.99–1.00).
Diagnostic phase
Table 2 shows the numbers of diagnostic procedures for palpable
and nonpalpable lesions in the scenarios (B) (NLBB) and (C)
(LCNB) (model calculations). In the NLBB scenario, 156400
women (61000 with palpable lesions and 94600 with nonpalpable
lesions) undergo NLBB; this is 64% of all women referred because
of a positive screen examination. In the LCNB scenario, 165100
referred women (68%) undergo biopsy: 62100 have palpable
lesions and undergo NLBB, 103000 women have nonpalpable
lesions and are scheduled for LCNB. Of the 103000 women with
nonpalpable lesions, 29900 finally undergo NLBB.
In the NLBB scenario, 116500 cancers are detected at screening
(4.8 per 1000 women screened): 16400 (14.1%) in situ cancers
(DCIS), 42700 (36.6%) T1a or T1b tumours, and 57400 (49.3%)
T1c or T2þ tumours. In the LCNB scenario, 115800 cancers are
detected at screening (4.7 per 1000 women screened). The tumour
size distribution is somewhat less favourable, with 15700 (13.5%)
in situ tumours, 42500 (36.7%) T1a or T1b tumours, and 56700
(49.8%) T1c or T2þ tumours.
Effects and costs
Table 3 displays the estimated impact on breast cancer mortality
and (quality-adjusted) life-years. Without screening, 351364
women would die of breast cancer (effect over 100 years, 0%
discounted). In scenario (B) (NLBB), breast cancer mortality
would be reduced by 31195 deaths (8.9%), that is, saving 514000
life-years. Screening with LCNB as diagnostic work-up for
nonpalpable lesions (scenario (C)) would prevent 31029 breast
cancer deaths (8.8%), thereby saving 511000 life-years. If LCNB
were to be implemented and replace NLBB, an extra six women
would die of breast cancer for each year of screening.
Without screening, the total cost of the management of breast
cancer would be d4369 million (3% discounted) for the next 100
years, of which d910 million (21%) would be spent on diagnostics.
If screening is introduced, the total costs would increase by
d307 million (7.0%) with NLBB as diagnostic work-up and by
d294 million (6.7%) if LCNB is applied. Thus, the net (dis-
counted) cost reduction of LCNB compared with NLBB would
be d13 million, which can be mainly attributed to a reduction in
diagnostic costs.
Cost-effectiveness and sensitivity analysis
The costs per life-year gained resulting from screening would be
d1515 with NLBB and d1459 for screening with LCNB (both costs
and effects 3% discounted). The incremental cost-effectiveness
ratio of NLBB vs LCNB is about d12482 per life-year gained, that is
extra costs of d12.70 million for NLBB compared to LCNB for 1017
additional life-years gained by NLBB.
Table 4 shows the results of the sensitivity analyses. At 5%
discount rate, the incremental cost-effectiveness ratio rises to
d17588 (extra costs of d10.13 million for NLBB compared to LCNB
to gain 576 additional life-years, both costs and effects 5%
discounted). With sensitivity of LCNB of 0.99, the incremental
cost-effectiveness ratio of NLBB vs LCNB was the highest (d74378
per extra life-year gained, both costs and effects 3% discounted).
The low cost of LCNB resulted in an incremental cost-effectiveness
ratio of d21430. The high cost of LCNB and lower thresholds for
breast biopsy resulted in negative incremental cost-effectiveness
ratios (lower costs of NLBB compared to LCNB, and no additional
life-years gained).
DISCUSSION
The current study shows that LCNB may be considered a cost-
effective alternative to NLBB, that is, considerable cost savings are
achieved at probably acceptable losses in terms of life-years. We
estimated that, with the introduction of LCNB, costs of diagnosis
and (primary) treatment of breast cancer would decrease by about
d500000 per year. Continued use of NLBB, on the other hand,
Table 2 Number of biopsies and breast cancers diagnosed with NLBB
and LCNB
a as diagnostic procedure for breast lesions detected at
screening
b (0% discounted)
NLBB
scenario (B)
LCNB
scenario (C)
Within the context of screening programme
No. of women undergoing biopsy ( 1000) 156.4 165.1
LCNB (nonpalpable lesions only) 0 73.1
c
NLBB 156.4 92.0
Palpable lesions 61.9 62.1
Nonpalpable lesions 94.6 29.9
d
No. of screen-detected cancers ( 1000) 116.5 115.8
LCNB (nonpalpable lesions only) 0 39.6
NLBB 116.5 76.2
Palpable lesions 57.4 57.7
Nonpalpable lesions 59.0 18.6
Outside screening programme
No. of women undergoing biopsy (NLBB
only) ( 1000)
1434.3 1435.2
Palpable lesions 1231.7 1232.3
Nonpalpable lesions 202.6 202.9
No. of breast cancers diagnosed ( 1000) 789.3 789.8
Palpable lesions 706.1 706.4
Nonpalpable lesions 83.2 83.4
aIncluding additional NLBB for benign or high-risk lesions at LCNB.
bThe screening
programme consists of biennial screening mammography for women aged 50–75
years, and is carried out during a period of 27 years.
cIn an additional 6200 women
with nonpalpable lesions, the histological diagnosis of the core biopsy was normal
tissue or high-risk lesion; these women therefore undergo NLBB.
dOf 29900 women
with nonpalpable lesions, 6200 underwent LCNB first, which led to the diagnosis of
normal tissue or high-risk lesion.
Cost-effectiveness of stereotactic large-core needle biopsy
JH Groenewoud et al
387
British Journal of Cancer (2004) 90(2), 383–392 & 2004 Cancer Research UK
C
l
i
n
i
c
a
lwould save more life-years. The pertaining incremental cost-
effectiveness ratio of continued NLBB vs LCNB, that is, about
d12500 per life-year saved, may be ‘borderline’ in political
decision-making about health-care services in the Netherlands,
and will be well within the bounds of acceptable cost-effectiveness
in many other countries. Further evaluation of quality of life in
patients who underwent LCNB vs NLBB might be undertaken for a
more elaborate comparison of particularly the long-term effects of
LCNB vs NLBB in terms of quality-adjusted life-years.
Sensitivity analyses show that the incremental cost-effectiveness
ratio of NLBB vs LCNB is most sensitive to relatively small
variations in the sensitivity of LCNB. We considered NLBB as the
gold standard diagnostic procedure, assuming 100% sensitivity. A
recent study into the diagnostic accuracy of open-breast biopsy,
however, showed that the sensitivity of open-breast biopsy
dropped to 0.99 after 2 years of follow-up and to 0.96 after 5
years of follow-up, when taking into account the so-called interval
lesions (Verkooijen et al, 2000). If the sensitivity of core biopsy
and the sensitivity of open-breast biopsy indeed prove to be equal,
then LCNB would dominate open-breast biopsy for all outcomes,
that is, being the strategy with less morbidity and lower costs.
Similarly, future developments of minimal invasive diagnostic
techniques, such as vacuum-assisted biopsy, will probably have no
further favourable effect on the cost-effectiveness, as long as the
sensitivity of such technique is comparable to that of LCNB and
costs are higher. However, for breast lesions consisting of
microcalcifications only, vacuum-assisted biopsy might become a
relevant alternative because the diagnostic accuracy of LCNB is
significantly lower for such lesions than for other mammographic
lesions (Pijnappel, 2002).
The cost of LCNB is another important factor for the cost-
effectiveness. Centralisation of stereotactic equipment for LCNB,
which implies lower costs per procedure, would be advisable from
an economic perspective (Buijs-van der Woude et al, 2001). In case
the costs of LCNB would considerably increase as compared to the
base case situation, this might at the extreme result in a dominance
of NLBB over LCNB, that is, the LCNB scenario would be more
expensive and simultaneously result in an increase in breast cancer
mortality. A related question is whether LCNB, being a less-
invasive diagnostic procedure, would also be applied to women
with nonpalpable breast lesions, who currently would have had no
biopsy at all. The latter effect may lead to an increase in overall
Table 3 Mortality effects, cost and cost-effectiveness of three scenarios: no breast screening, screening with NLBB as diagnostic work-up and screening
with LCNB as diagnostic work-up
Scenario (B) (NLBB) Scenario (C) (LCNB)
Scenario (A) (no screening) (difference with no screening)
Discount rate 0% 3% 0% 3% 0% 3%
Effectiveness
Deaths from breast cancer 351364 140520  31195  16180  31029  16099
Per year of screening  1155  1149
Life-years lost from breast cancer ( 1000) 6374 2395  513.9  202.6  511.2  201.6
Costs ( 10
6d)
Screening 0 0 +635 +432 +635 +432
Diagnostics 1802 910  70  40  93  55
Primary treatment 3059 1296 +87 +81 +91 +83
Follow-up 1136 454 +56 +30 +55 +29
Palliative care 4272 1708  379  197  377  196
Total 10269 4369 +328 +307 +310 +294
Cost-effectiveness
a (d)
Costs per life-year gained — — 639 1515 606 1459
aTo calculate the cost-effectiveness, the difference in costs between the situation without mass screening (scenario (A)) and that with mass screening (scenarios (B) and (C),
respectively) is divided by the difference in effects.
Table 4 Cost-effectiveness of LCNB and incremental cost-effectiveness ratio of NLBB vs LCNB (3% discounted); sensitivity analyses
Parameter varied Value
Cost per
life-year gained;
LCNB vs no mass
screening
a (d)
ICER of NLBB
vs LCNB
b (d)
None (baseline variant)
c 1459 12482
Discount rate 0% 606 6891
5% 2097 17588
Sensitivity of LCNB 0.96 1469 6618
Sensitivity of LCNB (high) 0.99 1450 74378
Costs of LCNB (low) d189 1414 21430
Costs of LCNB (high) d611 1538  3077
Costs of admission for NLBB (day care, 4% complications that require hospitalisation) d137 1449 6326
Threshold for breast biopsy in the LCNB scenario (15% threshold) 0.15 1546  4705
Threshold for breast biopsy in the LCNB scenario (0% threshold) 0.00 1632  21687
Threshold for breast biopsy in the LCNB scenario (15% threshold); costs of LCNB (low) 0.15/d189 1485 7297
Proportion of nonpalpable suspicious breast lesions at screening by mammography 775% 1496 4625
aThe cost per life-year gained is calculated through division of the difference in costs between the situation without mass screening (scenario (A)) and that with mass screening
(scenario (C)) by the difference in effects.
bICER¼incremental cost-effectiveness ratio. The ICER is calculated by dividing the difference in total cost of NLBB and LCNB by the
difference in life years gained.
cAssumptions for the baseline variant are: 3% discount rate; sensitivity of LCNB 0.97; cost of LCNB d343; threshold for breast biopsy 30%;
proportion of nonpalpable tumours (all DCIS and tumours in stages Ia and Ib) about 60%.
Cost-effectiveness of stereotactic large-core needle biopsy
JH Groenewoud et al
388
British Journal of Cancer (2004) 90(2), 383–392 & 2004 Cancer Research UK
C
l
i
n
i
c
a
lexpenditures, yet, might result in an increasingly favourable cost-
effectiveness of LCNB due to economies of scale (decrease of costs
per procedure). In our study, however, we found that a lower
threshold for breast biopsy resulted in a more favourable
incremental cost-effectiveness ratio of NLBB compared to LCNB,
even if low costs of LCNB were taken into account. Thus, from the
payers’ perspective, a change in practice in terms of lower
thresholds for referral due to the introduction of LCNB would
result in an increase in costs without significant health effects. It
would appear that, with the advent of LCNB, strict guidelines for
referral should be continued.
A trend towards shorter hospitalisation or towards the outpatient
setting for NLBB, which is common in other countries, will result in
lower costs of NLBB procedures. Also, this would reduce the
incremental cost-effectiveness ratio of NLBB compared to LCNB.
We further assumed that, if LCNB became widespread, FNA
cytology would not be undertaken. In our country, preoperative
FNA cytology – requiring specific expertise and not giving definite
pathologic confirmation of tumour type – is performed on a
relatively small scale. The role of FNA cytology is likely to become
less important after the introduction of LCNB, but whether actual
practice will mirror this assumption needs to be seen.
The MISCAN model simulates the effect of replacing NLBB by
LCNB in women with nonpalpable breast lesions detected at
screening. The model was not built to simulate the health effects
and costs of LCNB for nonpalpable lesions that are detected
outside the screening programme. In the Netherlands, the number
of nonpalpable lesions detected outside the context of the breast
cancer-screening programme is even larger than the number
detected at screening. Had we been able to take into account all
nonpalpable lesions, implementation of LCNB would have resulted
in a further decrease of costs and an increase in life-years lost,
assuming that the test characteristics of LCNB are similar for
nonpalpable lesions detected within and outside the breast cancer-
screening programme.
In the Netherlands, the breast cancer incidence is about 128 per
100000 women (all ages). This is comparable to the incidence in
the United Kingdom (about 136 per 100000 women). There is no
ground to assume that comparable test characteristics of LCNB
cannot be achieved in other Western medical settings too. Finally,
introduction of LCNB replacing NLBB for the diagnosis of
nonpalpable lesions on a large scale, particularly in countries
where breast screening results in an increased number of biopsies,
will have a marked impact on health care costs.
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Appendix
MIcrosimulation SCreening ANalysis (MISCAN) model
The core of the model consists of individual life histories,
which are generated as a Markov process of stages and transitions
in the natural history of breast cancer. The natural history is
modelled as the onset of breast cancer (i.e. the transition from no
disease to ductal carcinoma in situ (DCIS) or to a preclinical
invasive T1a status), the transition through four possible
preclinical invasive stages with increasing tumour diameters
(T1a: tumour 0.5cm or less in greatest dimension; T1b: tumour
more than 0.5cm but not more than 1cm in greatest dimension;
Structure of the MISCAN model for breast cancer  
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Figure A1 Structure of the MISCAN model for breast cancer.
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lT1c: tumour more than 1cm but not more than 2cm in greatest
dimension; and T2þ: including the stages T2 (tumour more than
2cm but not more than 5cm in greatest dimension), T3 (tumour
more than 5cm in greatest dimension) and T4 (tumour of any size
with direct extension to chest wall or skin)), and the transition
from one of the preclinical stages into a clinically diagnosed
stage (DCIS, T1a, T1b, T1c or T2þ) until the patient dies
from breast cancer or from other causes (see Figure A1).
Transitions between stages depend on transition probabilities
(see Table A1) and dwelling time distributions. Durations are
generated from exponential distributions with stage- and age-
dependent mean. Breast cancer screening is introduced as an
intervention in the natural history, possibly resulting in the
detection of breast cancer in earlier (preclinical) stages. Early
detection allows early diagnosis and treatment and results in
improved prognosis, that is, a reduction of breast cancer-specific
morbidity and mortality.
Key parameters in the model are the mean duration of the
preclinical screen-detectable stages, the sensitivity of the screening
test and the improvement in prognosis after screen detection. The
latter is defined as 1 minus the ratio of the risk of dying of screen-
detected breast cancer divided by the risk if the same cancer had
been diagnosed in the absence of screening. Age-specific assump-
tions with regard to the duration of the screen-detectable
Table A1 Important model parameters on natural history and screening in the MISCAN breast cancer model
Mean duration (years) of screen-detectable preclinical stage by age
Stage 40 50 60 70
Preclinical DCIS 5.2 5.2 5.2 5.2
Preclinical T1a 0.1 0.1 0.1 0.2
Preclinical T1b 0.4 0.5 0.7 0.9
Preclinical T1c 0.8 1.0 1.5 1.8
Preclinical T2+ 0.6 0.8 1.1 1.4
Long-term survival by clinical stage and age
Age DCIS T1a T1b T1c T2+
40 1.000 0.857 0.787 0.628 0.417
50 1.000 0.855 0.785 0.626 0.412
60 1.000 0.831 0.748 0.562 0.312
70 1.000 0.851 0.777 0.612 0.391
Probability of surviving by time since diagnosis and stage
Time since diagnosis T1a T1b T1c T2+
1 year 0.935 0.951 0.953 0.907
3 years 0.745 0.854 0.838 0.698
5 years 0.601 0.627 0.614 0.521
7 years 0.497 0.481 0.437 0.399
10 years 0.386 0.295 0.205 0.304
20 years 0.201 0.182 0.145 0.132
30 years 0.124 0.108 0.081 0.072
50 years 0.000 0.000 0.000 0.000
Sensitivity of mammography by stage and age
Stage Age 40–44 years Age 45–49 years Age X50 years
Preclinical DCIS 24% 32% 40%
Preclinical T1a 39% 52% 65%
Preclinical T1b 48% 64% 80%
Preclinical T1c 54% 72% 90%
Preclinical T2+ 57% 76% 95%
Reduction in risk of dying of breast cancer by stage in which (pre)cancer is detected
Stage Reduction in risk
Preclinical DCIS 100%
Preclinical T1a 89.2%
Preclinical T1b 81.4%
Preclinical T1c 56.7%
Preclinical T2+ 39.5%
Health stage Duration (de Haes et al, 1991) Utility (de Haes et al, 1991)
Terminal illness 1 month 0.712
Palliative therapy+chemotherapy 4 months 0.469
Palliative therapy+radiotherapy 1 month 0.419
Palliative therapy+surgical therapy 5 weeks 0.383
Palliative therapy+hormonal therapy 14 months 0.337
Initial chemotherapy 6 months 0.283
Initial radiotherapy 2 months 0.197
Initial surgery 2 months 0.133
Initial hormonal therapy 2 years 0.180
Disease-free 2 months–1 year after mastectomy 10 months 0.156
Disease-free 2 months–1 year after BCT 10 months 0.086
Disease-free 41year after mastectomy 1 year 0.053
Disease-free 41 year after BCT 1 year 0.040
Screening attendance 1 week 0.006
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have been validated using the results of the Dutch breast cancer-
screening programme (van den Akker-van Marle et al, 1999). The
improvement in prognosis is based on the results of Swedish
randomised trials (de Koning et al, 1995). Other model parameters
describe particular screening characteristics (screening ages,
interval and attendance rate).
The output of the model yields a number of estimates of the
effect of screening and subsequent outcome. The numbers of
women invited and screened are assessed, as well as the resulting
number of true-positive and false-positive test results, and the
number of cancers diagnosed outside the screening programme.
The output also includes the numbers of diagnostic procedures for
breast tumours detected at screening and for breast tumours
detected outside the context of the breast cancer-screening
programme, and the number of breast cancer therapies. Moreover,
the model calculates the number of breast cancer deaths and life-
years lost due to cancer.
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